Key Highlights / Executive Takeaways:
• Expanded collaboration deepens trust between LabGenius Therapeutics and Sanofi, reinforcing AI/ML as a core engine for next-generation antibody optimisation;
• EVA™ platform to co-optimise therapeutic NANOBODY® proteins across multiple new inflammation targets, improving speed, precision, and success probability;
• Signals growing pharma confidence in AI-driven protein engineering to unlock differentiated biologics with superior therapeutic profiles.
Scaling AI-Driven Antibody Optimisation: Building on the success of their initial partnership, LabGenius Therapeutics will deploy its EVA™ machine-learning platform to optimise NANOBODY® molecules against multiple new inflammatory disease targets, demonstrating how iterative AI-guided design can systematically enhance antibody performance across complex biological parameters.
Combining AI Intelligence with Biologics Expertise: The collaboration uniquely integrates LabGenius’ strength in ML-driven antibody co-optimisation with Sanofi’s deep expertise in NANOBODY® development, creating a powerful end-to-end discovery framework capable of engineering proteins with enhanced efficacy, stability, and developability.
Accelerating Inflammation Drug Discovery Pipelines: By focusing on inflammation, an area with high unmet medical need and biologic complexity, the partnership aims to shorten development timelines and improve candidate quality, potentially translating into faster delivery of next-generation biologics for patients with chronic and immune-mediated diseases.
Broader Signal for AI Adoption in Biopharma: This second collaboration underscores a broader industry shift, where leading pharmaceutical companies increasingly rely on AI-native discovery partners, validating machine learning and automated experimentation as essential tools for solving hard-to-engineer antibody challenges at scale.
About LabGenius Therapeutics
LabGenius Therapeutics is a London-based drug discovery company pioneering the development of next-generation therapeutic antibodies through the integration of artificial intelligence, machine learning, robotic automation, and synthetic biology. Its proprietary EVA™ platform enables rapid, data-driven co-optimisation of antibodies across multiple therapeutic parameters, significantly improving discovery efficiency and candidate quality. LabGenius operates a hybrid business model, combining strategic partnerships with biotech and pharmaceutical companies alongside the advancement of its own wholly owned therapeutic pipeline.
About Sanofi
Sanofi is a global biopharmaceutical company focused on improving people’s lives through the discovery, development, and delivery of innovative medicines and vaccines. With deep expertise across immunology, inflammation, oncology, rare diseases, and vaccines, Sanofi leverages advanced biologics platforms and cutting-edge technologies to address complex medical challenges. The company’s strong commitment to scientific innovation and strategic collaborations positions it at the forefront of translating breakthrough research into transformative therapies for patients worldwide.
By
